Application of MEMS in Drug Delivery 151
ﬁbrinogen layer covered the stent surface further inducing platelet activation and
In 2001, drug-eluting stents (DES) were introduced as a strategy to minimize
restenosis and requirement for reintervention. The currently available polymer-
coated stents contain antiproliferative agents which elute locally at placement
location to prevent neointimal hyperplasia. At two-year follow-up using both an-
giography and ultrasound, the clinical safety of DES was further established with
minimal late lumen loss observed.
A recent pooled analysis demonstrated a 74%
reduction in the risk of target lesion revascularization for both sirolimus-eluting
stents (SES) and paclitaxel-eluting stents (PES) compared to BMS.
90% of all stents placed in the United States and Europe are DES. Despite the en-
thusiasm that resulted with the advent of DES, incomplete endothelialization and
stentthrombosis continue to plague these devices. Despite therapeutic regimens
post-placement, late stent thrombosis (LST), deﬁned as occurring > 30 days post-
stent insertion, remains a signiﬁcant complication in patients with DES. Late stent
thrombosis carries a 45% mortality rate.
Conor Medsystems (CMS) had proposed a solution to enhance the perfor-
mance of stent technology by developing a stent platform which is capable of
ﬂexible and controllable pharmacokinetics proﬁles. Micromachining technology
has been used to create strategically placed drug depots within the depth of the
stent wall. The deep reservoirs of CMS stent were designed to provide greater dose
capacity than thin surface coatings (e.g., DES), allowing these stents to potentially
deliver more drug for an extended period of time, if required. Presently, the
technology is fairly new, and independent clinical feedback is further required.
Recently, in a 1,700 patients clinical trial, Krucoff et al reported that there were no
signiﬁcant beneﬁts to using CMS stents compared to the traditional DES.
7.3 THE DYNAMIC BETWEEN BIOCOMPATIBILITY AND
The onset of the inﬂammatory and wound healing response resulting from the
placement of BioMEMS in situ affects their biofunctionality. Protein adsorption,
cellular adhesion, and ﬁbrous encapsulation are normal inﬂammatory and wound
healing phenomena which occur following implantation of any material or device.
Consequently, the role of the in vivo environment as it interacts with a
BioMEMS device must be understood and acknowledged. Critical medical device
development limitations imposed by the intended in vivo placement must be recog-
nized and incorporated early into the idea and prototype design and development.
The fundamental hurdle encountered by BioMEMS in reaching a commercial po-
sition today is directly linked to the initial development of these devices, at times
taking place in an alternative reality where biology is inconsequential, because the
role of the biological environment seems to be neglected.
SO13997_text.indd 159SO13997_text.indd 159 26/01/2011 3:50 PM26/01/2011 3:50 PM